• #421 Bridging Genetic Testing and Patient Advocacy: From Diagnosis to Support
    Nov 20 2026
    A genetic diagnosis can provide long-awaited answers, but for patients and families, it often marks the beginning of a new journey. From understanding test results and connecting with others who share a diagnosis to navigating research opportunities and accessing care, support beyond the genetics clinic is essential. In this episode of DNA Today, host Kira Dineen is joined by two fellow genetic counselors, Jessica Shiles Hess, Associate Director of Patient Advocacy and Engagement at GeneDx, and Karmen Trzupek, Senior Director of Scientific Programs at Global Genes, to explore how partnerships between genetic testing laboratories and patient advocacy organizations can better support the rare disease community. Together, they discuss how advocacy has evolved from providing community support to actively advancing research and therapeutic development. They also examine persistent barriers to genetic testing, the challenges of interpreting uncertain results, and how laboratories and advocacy organizations are collaborating to improve education, expand access, and connect families with meaningful resources. From GeneDx's patient support services and data-sharing initiatives to Global Genes' Rare Concierge program and efforts to reach underserved communities, this conversation highlights how collaboration can help bridge the gap between receiving a diagnosis and knowing what comes next. Episode Discussion Topics The evolving role of patient advocacy: How patients, caregivers, genetic counselors, and advocacy organizations are driving education, research, policy, and therapeutic development.Global Genes and the rare disease community: How the organization supports condition-specific advocacy groups through education, mentorship, research infrastructure, and community resources.Laboratory and advocacy partnerships: How GeneDx collaborates with Global Genes and other organizations to develop genetic testing education, support research, and help families navigate the diagnostic journey.Data sharing and gene discovery: The importance of ClinVar, GeneMatcher, and collaborative research in improving variant interpretation and advancing rare disease diagnosis.Barriers to genetic testing: Geographic disparities, limited access to specialists, insurance coverage, financial challenges, health literacy, and underrepresentation in genomic databases.Supporting genetic counselors and healthcare providers: GeneDx's genetic counseling services, educational resources, financial assistance programs, sponsored testing pathways, and condition-specific report resources.Navigating variants of uncertain significance (VUS): Why clinical context matters, when connecting families with advocacy organizations may be helpful, and how reinterpretation can provide new insights over time.Connecting families with rare disease resources: How Global Genes' Rare Concierge program supports patients, caregivers, and healthcare professionals seeking guidance.Expanding testing access in underserved communities: A collaboration involving Global Genes and GeneSprout, including a pilot initiative focused on rural Tennessee communities.The future of rare disease advocacy: Why collaboration among laboratories, healthcare providers, researchers, and patient organizations is essential for improving access to diagnosis and advancing research. About the Guests Jessica Shiles Hess, MSc GC, CPC, is the Associate Director of Patient Advocacy and Engagement at GeneDx. A genetic counselor with a career focused on rare disease, Jessica works to strengthen partnerships between genetic testing laboratories and patient advocacy organizations. Her work emphasizes genetic testing education, access to diagnostic services, patient support resources, and collaboration that helps families navigate the genetic testing journey and connect with research opportunities. Karmen Trzupek, MS, CGC, is the Senior Director of Scientific Programs at Global Genes. With a background in rare disease genetics, genetic counseling, and telehealth services, Karmen focuses on helping patient advocacy organizations develop the scientific knowledge, research infrastructure, and partnerships needed to advance rare disease research. Her work supports advocacy leaders working to move their communities toward better diagnostics, treatments, and ultimately improved outcomes. Resources & Links Patient Advocacy and Support GeneDx – Genetic testing, patient education, genetic counseling support, and resources for healthcare providers.GeneDx Advocacy – Learn how GeneDx supports advocacy organizationsGlobal Genes – Resources, education, research programs, and support for rare disease advocacy organizations, patients, and families.Global Genes Rare Concierge – A resource for individuals, families, and healthcare professionals seeking guidance and connections within the rare disease community.Courageous Parents Network – Educational resources and support for families caring for children with...
    Show More Show Less
    38 mins
  • #420 NSGC 2026: Ambry's Whole Genome Sequencing and BillionToOne's Unity Confirm
    Nov 14 2026
    In this episode, we're coming to you from Baltimore for the National Society of Genetic Counselors (NSGC) 2026 Annual Conference! From new approaches to whole genome sequencing to the ability to analyze intact fetal cells through a pregnant person’s blood sample, we're exploring two exciting advances in genetic testing that could change how patients receive answers. Host Kira Dineen sits down with experts from Ambry Genetics and BillionToOne to discuss new technologies unveiled at the conference, their clinical applications, and how they could improve diagnostic accuracy and accessibility. We also celebrate Genetic Counselor Appreciation Day, highlight memorable moments from NSGC 2026, and share a special thank-you following Kira's recognition with the NSGC Leader in Community Engagement Award! Featured Guests Thomas "TJ" Slavin Jr., MD, is the Chief Medical Officer of Ambry Genetics and a medical geneticist. He joins us to discuss Ambry Genetics' newly launched whole genome sequencing offerings, GenomeNext and GenomeReveal, and how integrating RNA analysis, pangenome references, and proactive reanalysis could help end the diagnostic odyssey for more families. Jennifer "Jen" Hoskovec, MS, CGC, is Vice President of Medical Affairs at BillionToOne and a past president of NSGC (2014). She returns to DNA Today to introduce Unity Confirm, a new prenatal testing option that isolates and sequences intact circulating placental cells from a pregnant person’s blood to provide additional information following high-risk NIPT results. In This Episode We Discuss Ambry Genetics: Whole Genome Sequencing, RNA Analysis, and the Pangenome How Tempus' acquisition of Ambry Genetics brings together tumor sequencing and germline testing capabilities.Why Ambry chose 2026 to launch GenomeNext and GenomeReveal and how whole genome sequencing is changing rare disease diagnostics.How RNA analysis can help clarify variants of uncertain significance (VUS), particularly variants that may affect RNA splicing.Why incorporating a human pangenome reference can improve variant detection across diverse ancestral populations and help address disparities in genetic testing.How Ambry's Patient for Life program proactively reanalyzes genetic data and contacts providers when new evidence leads to clinically meaningful changes.Why identifying dual genetic diagnoses is increasingly important and how ongoing reanalysis can reveal additional explanations for a patient's symptoms. Clarification - Dr. Salvin mentioned Tempus is "the largest tumor sequencing company", it’s important to note that this is in the context of comprehensive genomic profiling (CGP). BillionToOne: Unity Confirm and Cell-Based Prenatal Testing How Unity Confirm differs from traditional cell-free DNA screening by isolating intact circulating extravillous trophoblasts from a pregnant person’s blood.How sequencing individual placental cells can provide additional information following a high-risk NIPT result.Why Unity Confirm is positioned as an additional testing option rather than a replacement for diagnostic procedures such as chorionic villus sampling (CVS) or amniocentesis.How this technology could help patients who decline invasive testing or face geographic, financial, or gestational-age barriers to accessing diagnostic procedures.The limitations of analyzing a small number of cells, particularly when considering placental mosaicism and conditions such as Turner syndrome.How staining techniques and genetic comparisons help distinguish placental trophoblasts from maternal white blood cells.How genetic counselors can integrate another source of prenatal information into patient-centered conversations about screening, diagnosis, and reproductive decision-making. Resources & Links NSGC Annual Conference National Society of Genetic Counselors (NSGC) – Learn more about NSGC, its annual conference, and resources for genetic counseling professionals. Ambry Genetics and Whole Genome Sequencing Ambry Genetics – Explore Ambry's clinical genetic testing services and resources. GenomeNext and GenomeReveal Launch Announcement – Learn how Ambry integrates whole genome sequencing, RNA analysis, pangenome references, and ongoing reanalysis to improve rare disease diagnosis. GenomeNext and GenomeReveal – Explore the technologies and clinical capabilities behind Ambry's new whole genome sequencing offerings. Patient for Life White Paper – Learn how Ambry's proactive reanalysis program identifies new diagnostic findings as genetic knowledge evolves. Tempus AI – Learn about Ambry's parent company and its work in precision medicine. Fact Check: Kira misspoke when she said Ambry has been analyzing RNA as part of clinical testing for 15 years, she was thinking of Ambry offering the first clinical exome as that was launched in 2011. BillionToOne and Prenatal Testing BillionToOne – Explore the company's prenatal genetic testing technologies. Unity Confirm ...
    Show More Show Less
    31 mins
  • #419 Optical Genome Mapping and Long-Read Sequencing: Unlocking Rare Diagnoses
    Nov 6 2026
    What happens when traditional genetic testing leaves patients and families without answers? Emerging technologies like optical genome mapping (OGM) and long-read sequencing are expanding what laboratories can detect, from complex structural variants to difficult-to-analyze repetitive regions of the genome. These advances are already changing clinical testing strategies and helping uncover diagnoses that previously remained out of reach. In this episode, we welcome back Dr. Nikhil Sahajpal, Assistant Laboratory Director at Greenwood Genetic Center (GGC), who previously joined us in Episode 362 to introduce optical genome mapping. Now, nearly two years after GGC began offering OGM clinically, Dr. Sahajpal shares how the technology is being integrated into rare disease diagnostics, including additional diagnostic findings in at least 5% of previously unsolved cases. The conversation takes a closer look at facioscapulohumeral muscular dystrophy (FSHD), a genetically complex condition involving D4Z4 repeat contractions, epigenetic changes, and inappropriate DUX4 expression. Dr. Sahajpal explains how OGM and short-read sequencing can work together to distinguish FSHD1 from FSHD2, and why the laboratory is evaluating long-read sequencing as a potential way to streamline this testing. We also explore targeted applications of OGM and long-read sequencing, including clarifying DMD duplications, mapping structural variant breakpoints, and determining whether variants are in cis or trans. Finally, Dr. Sahajpal discusses where long-read genome sequencing fits into the rare disease diagnostic workflow and whether a more comprehensive, unified genetic test could eventually reduce the need for multiple testing platforms. Episode Discussion Topics How optical genome mapping compares with karyotyping, FISH, and chromosomal microarrayGreenwood Genetic Center's clinical experience with OGM and its additional diagnostic yield in previously unsolved rare disease casesWhen OGM may serve as a reflex test following negative genome sequencingThe genetics of FSHD1, including D4Z4 repeat contractions, permissive haplotypes, and DUX4 expressionWhy chromosome 4 and chromosome 10 repeat regions complicate FSHD testingHow OGM and short-read sequencing contribute to distinguishing FSHD1 and FSHD2The potential for long-read sequencing to assess repeat size, sequence variants, and DNA methylationWhen long-read genome sequencing may be appropriate for patients with broad or nonspecific phenotypesHow targeted OGM can clarify DMD duplications and change carrier screening interpretationUsing targeted long-read sequencing to phase variants in recessive conditions without parental samplesThe limitations of phenotype-driven variant analysis and the future of comprehensive genomic testing Resources & Links Greenwood Genetic Center OGM CompleteOGM Targeted Facioscapulohumeral Muscular Dystrophy Type 2 (FSHD2) NGS PanelFSHD1Long-read Sequencing-Trio Analysis Long-read Sequencing-Targeted Analysis Sahajpal Completes Laboratory Fellowship at GGC and Joins FacultySahajpal NS, Mondal AK, Singh H, Vashisht A, Ananth S, Saul D, Hastie AR, Hilton B, DuPont BR, Savage NM, Kota V, Chaubey A, Cortes JE, Kolhe R. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers. Cancers (Basel). 2023 Jun 16;15(12):3214. doi: 10.3390/cancers15123214. PMID: 37370824; PMCID: PMC10296552. Relevant DNA Today Podcast Episode #362 Optical Genome Mapping: Detecting Structural Variants Missed by Traditional Tests (with guest Dr. Nikhil Sahajpal)#279 Reflecting on 50 Years of Greenwood Genetic Center#183 Dr. Miga and Dr. Phillippy on the Telomere to Telomere Consortium#182 Eric Green on the Complete Human Genome Project #145 Greenwood Genetic Center on Epigenetics Connect with DNA Today: You never have to wait long for a new episode of DNA Today, we release episodes every Friday! In the meantime, explore our library of over 400 episodes on Apple Podcasts, Spotify, DNAToday.com, or wherever you listen to podcasts. Just search “DNA Today.” Prefer to watch? The video version of this episode is available on our YouTube channel and DNAToday.com. Select episodes are filmed in person, including some at the iconic NBCUniversal studios. Discover more podcasts exploring genetics, genomics, medicine, and science from our network, Gene Pool Media: The Science Podcast Network. DNA Today is hosted and executive produced by Kira Dineen, MS, LCGC, CG(ASCP)CM. Liv Davidson is our Social Media Lead and Eric Knaus is our Digital Marketing and Automation Lead. Follow us at @DNATodayPodcast on all platforms including Instagram, X, BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. Questions, partnership inquiries, and guest pitches can be sent to info@DNAToday.com.
    Show More Show Less
    39 mins
  • #418 Hypophosphatasia Genetics: One Gene, Many Presentations
    Oct 30 2026
    How can variants in the same gene cause life-threatening disease in infancy for some individuals, while others experience mild symptoms or remain asymptomatic? Hypophosphatasia (HPP) challenges traditional expectations about genetic inheritance, with both autosomal dominant and autosomal recessive forms and a remarkably broad spectrum of clinical presentations. In this episode, recorded in person in Nashville, our guest is Dr. Kathryn Dahir, Professor of Medicine in the Division of Diabetes, Endocrinology, and Metabolism at Vanderbilt University Medical Center and Director of the Program for Metabolic Bone Disorders. Drawing on decades of experience caring for patients with rare skeletal conditions, Dr. Dahir explores the complex genetics of HPP and why understanding a patient's clinical presentation is just as important as interpreting their genetic test results. The conversation begins with a patient case that challenged Dr. Dahir's understanding of HPP. Initially treated for osteoporosis, the patient experienced recurrent fractures and worsening symptoms despite treatment. Further investigation revealed impaired bone mineralization, low alkaline phosphatase (ALP), and a single ALPL variant, illustrating how individuals with one affected copy of the gene can experience significant disease. Dr. Dahir explains how the ALPL gene encodes tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme essential for healthy bone mineralization, and how disruption of its activity contributes to the manifestations of HPP. We explore the differences between autosomal dominant and autosomal recessive inheritance, the challenges of predicting disease severity from genetic testing alone, and why even relatives carrying the same ALPL variant may have very different symptoms. Dr. Dahir discusses the importance of identifying variants in cis or trans, recognizing deletions and duplications, evaluating variants of uncertain significance, and considering how genetic modifiers, environmental exposures, and coexisting conditions can influence a patient's presentation. Finally, we discuss the evolving landscape of HPP genetic testing, including the importance of longitudinal follow-up, resources such as the global ALPL variant database, and ongoing efforts to improve variant classification. As genomic testing becomes increasingly accessible, this conversation highlights both its potential to improve rare disease diagnosis and the limitations of using genetics alone to predict an individual's future health. Episode Discussion Topics Dr. Dahir's clinical experience treating HPP and other rare metabolic bone disorders at Vanderbilt University Medical CenterWhy genetic testing must be interpreted alongside clinical symptoms, biochemical findings, and patient historyA patient case illustrating how HPP can be mistaken for osteoporosis and why low alkaline phosphatase is an important diagnostic clueHow the ALPL gene and tissue-nonspecific alkaline phosphatase (TNSALP) regulate bone mineralizationThe differences between autosomal dominant and autosomal recessive HPP and the challenges of distinguishing affected individuals from asymptomatic carriersWhy genotype-phenotype correlations in HPP are complex, even among family members with the same genetic variantThe importance of determining whether variants are in cis or trans and identifying deletions or duplications that some testing platforms may missHow modifier genes, epigenetics, medication exposures, and coexisting medical conditions may influence HPP symptoms and severityInterpreting variants of uncertain significance and the importance of genetic counseling, variant reclassification, and long-term follow-upThe role of the global ALPL variant database in improving classification and understanding the clinical significance of genetic variantsFuture opportunities to identify protective genetic factors and improve predictions of disease progression About the HPP Series This episode is the first in a three-part educational series about hypophosphatasia. Stay tuned for the next installment . Across the series, we explore the clinical spectrum and diagnosis of HPP, its genetic basis and variable expression, and considerations for genetic counseling and management. This series is sponsored by Alexion. The views expressed by the host and guests are their own. Resources & Links Vanderbilt University Medical CenterAlexion, AstraZeneca Rare Disease ALPL Gene Variant DatabaseSoft Bones: The U.S. Hypophosphatasia Foundation provides education, support, advocacy, and community resources for individuals and families affected by HPP.Explore Soft Bones’ HPP resources, including educational materials for patients, caregivers, and healthcare professionals. Publications Dahir KM, Below JE, Liu J, Javid A, Wang G, Bastarache L. Hypophosphatasia: low penetrance of pathogenic and likely-pathogenic ALPL variants identified through an unselected biorepository. J Bone Miner Res. 2026 Mar 2;41(3):...
    Show More Show Less
    35 mins
  • #417 ASHG 2026: Electronic Genome Mapping, AI in Genetics, & the Future of Research
    Oct 23 2026
    For the third year in a row, DNA Today is bringing you inside the American Society of Human Genetics (ASHG) Annual Meeting, and this year, we've taken our genetics coverage international! We're reporting from beautiful Montréal, Canada, where thousands of geneticists, researchers, clinicians, and industry leaders gathered to share the latest breakthroughs shaping the future of genomics. From cutting-edge technologies to big questions about the future of genetic medicine, there's no shortage of exciting science to unpack. And don't worry, we're bringing you all the highlights, no passport required, eh? In this episode, host Kira Dineen takes you behind the scenes of ASHG 2026 through two special segments recorded at the conference. First, we stop by the Nabsys booth to chat with Founder and CEO Barrett Bready, MD, about how Electronic Genome Mapping (EGM) is advancing our ability to detect structural variants. We explore how the technology compares with traditional approaches, its emerging applications in hematologic malignancies, and the latest research Nabsys is showcasing at ASHG. For our second segment, we're live on location! DNA Today teamed up with Wiley's Advanced Portfolio to co-host a special brunch featuring a live podcast recording right from the conference. With breakfast on the table and big questions on the menu, Kira moderated a conversation with leading genetics researchers and publishing experts about the discoveries, challenges, and opportunities shaping the field. From translating genetic findings into new therapies and harnessing AI to accelerate research to fostering interdisciplinary collaboration and rethinking the role of scientific publishing, this discussion goes beyond the conference presentations to explore where genetics is headed next. Whether you joined us in Montréal or are experiencing the conference from afar, consider this your front-row seat to some of the conversations shaping the future of genetics. We're serving up fresh science with a side of maple syrup, because when it comes to genetics, there's always more to discover, eh? Nabsys Segment Guest Barrett Bready, MD is Founder and CEO of Nabsys. He is passionate about the impact that advanced technology can have on the understanding of disease as well as on its diagnosis and treatment. He has raised $150 million to realize a new way of analyzing DNA that uses proprietary solid-state electronic nanodetectors to analyze very long molecules, with an initial focus on genomic structural variation. Barrett is an adjunct professor at Brown University where he lectures on the rapidly evolving business of life sciences. He serves as a commissioner of the I-195 Redevelopment District Commission, a major land redevelopment initiative in downtown Providence, RI with a focus on life sciences and other high-technology sectors. He has received numerous awards including, in 2011, Rhode Island Innovator of the Year, and in 2018, a career achievement award from the Warren Alpert Medical School of Brown University. Barrett graduated from the highly competitive Program in Liberal Medical Education (PLME) at Brown University where he received an M.D. and an Sc.B. in Physics and won the undergraduate physics award (the Lindsay Prize) and the Galletti Prize for physics in medicine. Nabsys Discussion Topics ASHG 2026 conference highlights and a presentation on electronic genome mapping (EGM) in hematologic malignanciesWhy genomic structural variants matter in cancer and rare diseaseHow traditional sequencing and cytogenetic approaches may leave gaps in detecting structural variationNabsys’ electronic genome mapping as a high-resolution, top-down approach to studying genome structureHow EGM uses electrical detection to read sequence-specific tags on long DNA moleculesIdentifying deletions, insertions, inversions, and translocations by comparing tag patternsHow EGM relates to traditional cytogenetic methods such as FISH and karyotypingThe nanochannel detection process and how DNA molecules affect ionic current as they pass throughNabsys’ relationship with Hitachi and the potential to scale the technologyNabsys’ goal of expanding access to structural variant detection and single-molecule insightsASHG posters on CRISPR-Cas9-mediated assay specificity and EGM applications for copy number variants in constitutional disordersThe potential for EGM to combine modalities and increase diagnostic yield over time Wiley Advanced Genetics Panelists Yuming Hu, PhD serves as the Editor-In-Chief for Advanced Genetics, which is a peer-reviewed, broad-scope, open-access journal dedicated to advancing gene-related research with a recently expanded scope. It includes not only human, animal, plant, and microbial genetics, genomics, and epigenomics, but also topics that employ genetic, omics technologies, bioinformatics, computational biology, and artificial intelligence as toolboxes for discovery and innovation. Dr. Hu received her B.Sc. and M.Sc...
    Show More Show Less
    42 mins
  • #416 How Baby KJ Became the First Patient Treated With Personalized CRISPR
    Oct 16 2026
    CRISPR has carried enormous promise since scientists first realized its potential to edit the human genome, but it has also raised some of the biggest ethical questions in modern genetics. In this episode, Kira Dineen sits down with Dr. Kiran Musunuru to trace the evolution of human gene editing, beginning with the controversial 2018 announcement that scientist He Jiankui had used CRISPR to edit human embryos in China, resulting in the birth of the world’s first gene-edited babies. The experiment, which targeted the CCR5 gene in an attempt to reduce susceptibility to HIV, sparked international condemnation and intensified debate over germline genome editing, where genetic changes could potentially be passed on to future generations. From there, the conversation shifts to a dramatically different application of CRISPR: treating serious genetic disease in an individual patient. Dr. Musunuru shares the remarkable story of Baby KJ, who was born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency and became the first patient to receive a personalized CRISPR-based therapy designed specifically for his genetic variant. The team developed KJ’s customized base-editing treatment in approximately six months, moving from identification of his variant through preclinical testing, manufacturing, regulatory review, and ultimately treatment. Dr. Musunuru explains how KJ’s therapy works, what researchers have learned from his response so far, and whether his case could establish a new pathway for treating patients with ultra-rare genetic conditions who may never fit into a traditional drug-development model. This interview was recorded in person at AGBT Precision Health in Coronado, California, we caught up with Dr. Musunuru after a presentation. Episode Discussion Topics: The 2018 announcement of the world’s first CRISPR-edited babies in ChinaWhy He Jiankui’s experiment targeting the CCR5 gene sparked global scientific and ethical backlashThe difference between editing embryos and germline cells versus editing somatic cells in a patientWhat the CRISPR babies controversy taught the scientific community about oversight, regulation, and responsible use of gene-editing technologyHow the field of CRISPR medicine has evolved since 2018How naturally occurring PCSK9 variants helped reveal a powerful target for lowering LDL cholesterol and preventing cardiovascular diseaseUsing CRISPR base editing to permanently turn down PCSK9 activity in the liver as a potential one-time treatment for high cholesterolThe development of PCSK9 gene-editing therapies for patients with familial hypercholesterolemia and premature coronary artery diseaseThe possibility of moving cardiovascular care from lifelong medications to durable, one-time genetic treatmentsHow cardiovascular gene editing helped pave the way for applying similar base-editing technology to rare diseases like Baby KJ’s CPS1 deficiencyWhat CPS1 deficiency is and why it can become life-threatening shortly after birthHow Baby KJ’s diagnosis created an opportunity to pursue a personalized gene-editing treatmentWhy KJ’s specific genetic variant was a candidate for base editingHow base editing differs from traditional CRISPR approaches that make double-stranded breaks in DNADeveloping a gene-editing therapy specifically for a single patientDelivering the gene editor to liver cells using lipid nanoparticlesWhy the liver is an especially promising target for in vivo gene-editing therapiesThe collaboration between researchers, clinicians, biotechnology companies, regulators, and KJ’s family that made the treatment possibleNavigating FDA review for a therapy that had never previously been given to a humanWhy KJ received multiple doses of the therapyEarly signs that the treatment was having an effect, including increased dietary protein tolerance and reduced dependence on nitrogen-scavenging medicationWhy researchers are careful not to describe KJ’s treatment as a cureThe importance of long-term monitoring for both effectiveness and potential safety concernsEvaluating off-target editing and other potential risks of personalized gene-editing therapiesWhether creating an individual therapy for a single patient can realistically become scalableMoving from an “N-of-1” treatment toward gene-editing platforms that could be adapted for multiple patients with different variantsHow regulatory frameworks may need to evolve for personalized genetic medicinesWhich other rare genetic diseases could potentially benefit from this approachWhat Baby KJ’s story could mean for the future of precision medicine and gene editing About Dr. Kiran Musunuru Kiran Musunuru, MD, PhD, MPH, ML, MRA, is the Barry J. Gertz Professor for Translational Research at the Perelman School of Medicine at the University of Pennsylvania. He is Director of the Genetic and Epigenetic Origins of Disease Program within the Penn Cardiovascular Institute, Scientific Director of the Penn Center ...
    Show More Show Less
    30 mins
  • #415 Achondroplasia Treatment Advances with Dr. Ravi Savarirayan
    Oct 9 2026
    Please note this episode is only available on our website, DNAToday.com under Episode 415, and access is limited to those in the United States. In just a few years, achondroplasia treatment has expanded from no approved precision medicines to multiple approaches targeting the condition’s underlying biology. In this episode, we continue our conversation with Dr. Ravi Savarirayan, a global leader in skeletal dysplasia care and a lead investigator across multiple achondroplasia clinical development programs. Dr. Savarirayan previously joined us on Episode 401, where we explored the first approved precision treatment for achondroplasia and international guidance for its use. This time, we take a broader look at the rapidly evolving achondroplasia treatment landscape, including how different therapeutic approaches target FGFR3 signaling, how researchers interpret clinical trial outcomes, and what results from the Phase 3 PROPEL 3 study of investigational infigratinib could mean for children and families. We also discuss why treatments cannot be reliably compared using results from separate clinical trials, the importance of studying outcomes beyond growth, and the questions that remain about long-term safety, functional benefits, treatment selection, and switching therapies. Thank you to BridgeBio for sponsoring this episode. Episode Discussion Topics How the achondroplasia treatment landscape has evolved in the last seven yearsHow achondroplasia affects more than heightHow current and investigational therapies target FGFR3 signaling in different waysWhat annualized growth velocity, height Z-scores, and body proportionality reveal in clinical trialsKey findings from the Phase 3 PROPEL 3 study of investigational infigratinibWhat researchers can and cannot yet predict about final adult height based on current dataWhy body proportionality may be an important clinical and functional outcomeHow researchers are evaluating potential effects on mobility, reach, independence, and daily activitiesThe long-term safety questions that remain when treatment begins in childhoodWhy results from separate achondroplasia trials should not be compared directlyHow families and healthcare providers can weigh treatment benefits, risks, administration, and personal goalsWhat is being studied in hypochondroplasia and other conditions involving overactive FGFR3 signaling Our Guest: Dr. Ravi Savarirayan Ravi Savarirayan is consultant clinical geneticist at Victorian Clinical Genetics Services, Professorial fellow at the University of Melbourne, and Group leader (Molecular Therapies at Murdoch Children’s Research Institute, Victoria, Australia. Professor Savarirayan received his MBBS from the University of Adelaide, Australia in 1990 and became a Fellow of the Royal Australasian College of Physicians in 1997. He was certified as a specialist in Clinical Genetics by the Human Genetics Society of Australasia in 1998 and was awarded his Doctor of Medicine from the University of Melbourne in 2004. He was awarded the Fulbright Professional Scholarship for Australia in 1998, and took this up at University of California, Los Angeles (UCLA). Professor Savarirayan’s primary research focus is on inherited disorders of the skeleton causing short stature, arthritis, and osteoporosis. He has published over 230 peer-reviewed articles and received over $35M in research funding, collaborating with researchers from 40 countries. His current clinical trial activities are pioneering disruptive new therapies for the treatment of genetic disorders. He was the global lead investigator of the clinical development program that identified vosoritide as the first precision therapy for children with achondroplasia. He was recently named one of the 30 “Brilliant minds” of the Murdoch Children’s Research Institute over the past 30 years, was awarded the Institute’s research excellence award in 2020, and is an NHMRC Leadership Fellow. Resources BridgeBio Achondroplasia Program Learn more about achondroplasia, FGFR3 biology, and BridgeBio’s clinical development program evaluating infigratinib.BridgeBio Achondroplasia Clinical Trials Information about the PROPEL clinical trials for infigratinib. “Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia” The article that Dr. Ravi mentioned in the episode that was published June 28, 2026 in The New England Journal of Medicine. Little People of America A nonprofit organization offering community, education, advocacy, events, and resources for people with dwarfism and their families. Relevant DNA Today Podcast Episodes Episode 401: The First Precision Medicine for Achondroplasia with Dr. Ravi Savarirayan Dr. Savarirayan first appearance on the show where he explains how the first approved precision treatment for achondroplasia works and discusses international consensus recommendations for counseling families, initiating treatment, monitoring outcomes, and considering when ...
    Show More Show Less
    2 mins
  • #414 How To Find Genetics Professionals Worldwide: The Global Genetics Directory
    Oct 2 2026
    When patients relocate or relatives living abroad need cascade testing, finding a qualified genetics professional in another country can be surprisingly difficult. The new Global Genetics Directory aims to change that through a free, verified, peer-to-peer resource connecting genetics and genomics professionals worldwide. In this episode of DNA Today, recorded in person at our studio, host Kira Dineen is joined by genetic counselor Monisha Sebastin, Founder and Principal Investigator of the Global Genetics Directory. Monisha explains how her international background and leadership within the genetics community revealed the need for a centralized global resource. We explore how the directory was developed with support from the prestigious Audrey Heimler Special Projects Award, how professionals are verified across different credentialing systems, and why the team chose a closed, consent-based model rather than a publicly searchable directory. Monisha also shares how the directory could strengthen cross-border patient care, cascade testing, professional collaboration, and access to genetics services around the world. Episode Discussion Topics Why finding genetics professionals in other countries can be challengingHow Monisha’s experiences in India and the United States shaped her perspective on global accessWhen international connections are especially important for patient care and cascade testingWhat genetics professionals around the world said they needed from a global directoryHow NSGC’s Audrey Heimler Special Projects Award supported the projectHow registration, credential verification, and directory searches workWhy eligibility is limited to credentialed genetics and genomics professionalsHow the directory accommodates differences in professional titles, credentials, and scopes of practiceWhy membership is freeThe benefits of a closed, peer-to-peer, and consent-based modelHow patients seeking care abroad can work with their current providersThe team’s vision for expanding the directory and strengthening international collaboration About Monisha Sebastin Monisha Sebastin, MS, LCGC, is the Founder and Principal Investigator of the Global Genetics Directory. She is also a senior pediatric genetic counselor in New York City, where she specializes in cardiogenetics and research. Monisha grew up in India and earned her undergraduate degree in genetic engineering before completing her genetic counseling training at Sarah Lawrence College. Her international background, clinical experience, and leadership within the global genetic counseling community helped inspire the development of the Global Genetics Directory. The directory was developed with support from the Audrey Heimler Special Projects Award for Monisha’s project, “Evaluating International Genomics Providers’ Needs and Perspectives on a Global Genomics Services Directory.” Resources & Links Global Genetics DirectoryTo email directly, contact@globalgeneticsdirectory.com National Society of Genetic Counselors (NSGC)NSGC’s Audrey Heimler Special Projects AwardFind A Genetic Counselor Directory Relevant DNA Today Podcast Episodes #109 Shenela Lakhani on Genetic Counseling in Qatar — Hear from Qatar’s first certified genetic counselor about establishing the profession in a new country and adapting counseling across cultures.#110 Gattaca, 22 Years Later with Catherine Mayo and Ale Cantu — Catherine Mayo’s first DNA Today appearance examines the film’s enduring relevance to genetic counseling, reproductive decision-making, and genetic discrimination.#114 Matt Burgess on Australasian Genetic Counseling — Explore genetic counseling education, certification, private practice, and healthcare delivery in Australia and across the Australasian region.#212 NSGC Recap 2022 — Meet Monisha and learn about the clinical care and compassion that earned her the Heart of Genetic Counseling Award, along with her work supporting international genetic counselors.#221 Genetic Counseling in South Africa with Samantha Bayley and Tina-Marié Wessels — Learn how genetic counseling is practiced and taught in South Africa, including barriers to expanding services and differences between its public and private healthcare systems.#259 NSGC 2023 Recap and Reflections with Catherine Mayo — Catherine Mayo returns to the show to discuss major themes and takeaways from the genetic counseling profession’s annual conference.#269 Computer Vision Diagnosing Genetic Disorders with Robert Boscacci — Meet the Global Genetics Directory’s web developer and site architect and hear how computer vision can support the diagnosis of genetic conditions.#286 Qatar Genome Program with Dr. Said Ismail — Explore the Middle East’s largest population-based genome initiative and its work to improve the representation of Qatari and Arab populations in genomic research.#311 Mock Cancer Genetic Counseling Session with Catherine Mayo — Hear Catherine Mayo ...
    Show More Show Less
    28 mins